JAYPIRCA (pirtobrutinib), FDA Approved for Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Available at Biologics by McKesson

CARY, N.C., Feb. 14, 2023 —Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by Lilly as a specialty pharmacy provider for JAYPIRCATM (pirtobrutinib) for the treatment of adult patients with relapsed or refractory mantle cell l...
Source: McKesson News - Category: Information Technology Source Type: news